Wegovy as a Slimming Drug: Clinical Evidence and Practical Realities

What the STEP 1 trial found about Wegovy's weight-loss effect

The cornerstone evidence for Wegovy as a slimming drug comes from the STEP 1 study: 68 weeks, semaglutide 2.4mg against placebo, in adults living with obesity. Participants lost an average of around 15% of their body weight. That is not a marketing figure; it is the primary endpoint result from a peer-reviewed trial, and it is the number NICE cited in its technology appraisal (TA875) when recommending semaglutide for use in specialist NHS weight-management services.

Context matters, though. Trial participants also followed a reduced-calorie diet and increased physical activity. The medicine reduced appetite substantially, making those changes easier to sustain — but it worked alongside lifestyle adjustment, not instead of it. The weight loss was also not linear; most of it occurred in the first 40 or so weeks, with a plateau thereafter. Knowing this before you start helps set realistic expectations and is something a prescriber will discuss with you.

A higher dose option has since expanded what is possible. The MHRA approved a 7.2mg weekly dose (and a dedicated single-dose pen for it) on 14 April 2026, with trials at that strength reporting average weight loss of around 20.7% over 72 weeks. You can read more about how the medicine itself is classified on the Wegovy drug overview page, which covers licensing and development in greater depth.

Who the licence actually covers, and what the prescriber looks at beyond BMI

If you are considering the Wegovy slimming jab, it helps to know that the UK marketing authorisation applies to adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 who also have at least one weight-related condition. That condition might be prediabetes, hypertension, high cholesterol, or obstructive sleep apnoea, among others. For some people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the relevant BMI thresholds sit 2.5 kg/m² lower under UK guidance.

BMI, though, is a starting point rather than a decision. A prescriber also considers your medical history, current medicines, and whether any contraindications apply. Medullary thyroid carcinoma, a personal or family history of MEN2, active pancreatitis, pregnancy, and breastfeeding are among the situations where Wegovy is not appropriate. Age matters too: the medicine is not licensed for under-18s. If you are on an oral contraceptive, your prescriber will advise on any additional precautions during early treatment.

It is worth spending sixty seconds checking that any online pharmacy you consider is listed on the GPhC pharmacy register before sharing personal or medical information with them. Legitimate dispensing of a prescription medicine requires a GPhC registration, and it is publicly verifiable in moments. For broader context on how the active ingredient in Wegovy is classified and studied, the semaglutide as a drug page explains the pharmacology.

Side effects: what the trial data shows and when to seek help

Gastrointestinal effects dominate the side-effect profile in the STEP programme. Nausea is the most frequently reported, followed by diarrhoea, constipation, vomiting, and reflux. These are most pronounced after starting treatment or after a dose increase, and for most people they ease within the first couple of weeks at each dose level. Fatigue, headache, and dizziness appear less commonly.

More serious but less frequent effects require prompt attention. Severe, persistent abdominal pain (particularly pain that spreads to the back) needs same-day medical assessment, as it can be a sign of pancreatitis. The MHRA has flagged acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines, and patients can report unexpected side effects directly via the Yellow Card scheme. Gallbladder symptoms, significant allergic reactions, and signs of severe dehydration following persistent vomiting or diarrhoea also warrant urgent contact with a healthcare professional.

The NHS patient-level information for semaglutide on the NHS website sets out the full side-effect list in plain language and is updated in line with current UK guidance. It is a reliable first check if something unexpected happens during treatment. For a broader look at how Wegovy compares to other weight-loss options available in the UK, the weight-loss treatment overview covers the landscape clearly.

NHS access versus the private route, and what cost actually covers

NICE's recommendation for semaglutide (TA875) is conditional: it applies within a specialist weight-management service, for a maximum of two years, with multidisciplinary support throughout. NHS eligibility thresholds are strict, and waiting lists for those services are commonly long. People who meet the criteria may wait months before treatment begins.

Private prescribing is the alternative, and it does not require a specialist referral. A GPhC-registered prescriber reviews your consultation, and if the medicine is clinically suitable, treatment can be dispensed quickly. The cost picture for private Wegovy is worth understanding before you commit: headline prices across the market range broadly by dose and provider, and what a quoted figure includes varies considerably. Some providers charge separately for the consultation, prescription, or delivery; others bundle everything. The Wegovy pricing page breaks down what those numbers typically represent and what to look for when comparing.

At nume, the price you see covers your consultation, prescription, treatment, and free next-working-day delivery. There are no subscriptions and no auto-renewals, every repeat order is reviewed by a prescriber before it is dispensed. Understanding the Wegovy drug name and how it relates to the active ingredient semaglutide can also help you make sense of what you are being prescribed and why different products exist on the market. You can find out more about how we work and who reviews your case on the about us page, or read our frequently asked questions for practical detail about the process. If you want to explore the weight loss drug Wegovy properly, the right next step is a clinical conversation rather than a purchase decision, and that conversation starts with a free consultation.

Start your free consultation and a GPhC-registered prescriber will review your details the same day.